Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
| Author | |
|---|---|
| Abstract |
:
Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of various ADAs used as add-on medication to metformin in T2DM patients from a nationwide cohort. |
| Year of Publication |
:
2018
|
| Journal |
:
Cardiovascular diabetology
|
| Volume |
:
17
|
| Issue |
:
1
|
| Number of Pages |
:
20
|
| Date Published |
:
2018
|
| URL |
:
https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0663-6
|
| DOI |
:
10.1186/s12933-018-0663-6
|
| Short Title |
:
Cardiovasc Diabetol
|
| Download citation |
